Last reviewed · How we verify
levofloxacin; metronidazole
This combination uses levofloxacin (a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV) and metronidazole (a nitroimidazole that damages bacterial DNA) to provide broad-spectrum anaerobic and aerobic bacterial coverage.
This combination uses levofloxacin (a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV) and metronidazole (a nitroimidazole that damages bacterial DNA) to provide broad-spectrum anaerobic and aerobic bacterial coverage. Used for Mixed aerobic and anaerobic bacterial infections, Intra-abdominal infections, Pelvic inflammatory disease.
At a glance
| Generic name | levofloxacin; metronidazole |
|---|---|
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Drug class | Fluoroquinolone + Nitroimidazole combination antibiotic |
| Target | Bacterial DNA gyrase, topoisomerase IV (levofloxacin); bacterial DNA (metronidazole) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Levofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in gram-negative and gram-positive bacteria. Metronidazole is a nitroimidazole antibiotic that is reduced to reactive intermediates inside anaerobic bacteria, causing DNA strand breaks and cell death. Together, they provide synergistic coverage against both aerobic and anaerobic pathogens, commonly used in mixed infections.
Approved indications
- Mixed aerobic and anaerobic bacterial infections
- Intra-abdominal infections
- Pelvic inflammatory disease
- Diabetic foot infections with mixed flora
Common side effects
- Nausea
- Diarrhea
- Metallic taste (metronidazole)
- Headache
- Tendinopathy (fluoroquinolone-related)
- QT prolongation
- Photosensitivity
Key clinical trials
- Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding" (PHASE3)
- Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study
- Fecal Molecular Susceptibility-guided Hp First-line Therapy (PHASE4)
- Fecal Molecular Susceptibility-guided Hp Rescue Therapy (PHASE4)
- Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection (PHASE4)
- Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
- Comparison of Two Treatment Regimens of Helicobacter Pylori Infection (PHASE4)
- Diagnostics of Chronic Endometritis in Infertility (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: